50 likes | 71 Views
Chronic Lower Back Pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is very common, and at one point, everyone must have faced this problem. Lower back pain that is long-term (for more than 3 months) is called CLBP. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe.<br><br>Read More- https://www.delveinsight.com/infographics/chroni
E N D
Chronic Lower Back Pain: An Overview Chronic Lower Back Pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is very common, and at one point, everyone must have faced this problem. Lower back pain that is long-term (for more than 3 months) is called CLBP. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe. Chronic Lower Back Pain Epidemiology Segmentation in the 7MM Total Prevalence of CLBP Total Diagnosed Prevalence of CLBP Gender-specific Diagnosed Prevalence of CLBP Age-specific Diagnosed Prevalence of CLBP Chronic Lower Back Pain Epidemiological Insights Observed in the 7MM (2021) The total prevalent population of Chronic Lower Back Pain in the 7MM was found to be 76.4 million. In the EU5 region, the total prevalent population of Chronic Lower Back Pain in Spain was found to be 8.7 million cases whereas in the UK, they were found to be 5.9 million cases. The total prevalent population of Chronic Lower Back Pain in Japan was estimated to be 12.7 million. Chronic Lower Back Pain Market Insight The market size of Chronic Lower Back Pain in the 7MM was found to be USD 6,227 million in 2021. Chronic Lower Back Pain Market Drivers Increasing patient pool Robust Pipeline Advantages of Stem Cell Therapy
Burden of illness Chronic Lower Back Pain Market Barriers Complicated heterogeneity of patients Implementation of best available evidence Usage of opioids in case of failure of other available therapeutic drugs Deviation toward alternate treatment methods from pharmacological treatment methods High cost and difficulties in back pain research Chronic Lower Back Pain Emerging Therapies The emerging drugs in the Chronic Lower Back Pain market are Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot) Semdexa (SP-102) Rexlemestrocel-L (MPC-06-ID) AMG0103 KLS-2031 ETX-810 ALLOD-2 FB3001 IDCT (rebonuputemcel) SX600 STA363 Clonidine Micropellets (STX-015) Tanezumab LY3556050 PP353
BRTX-100 VER-01 BM-MSC/ReSpine Chronic Lower Back Pain Key Players The key players working in the Chronic Lower Back Pain market are Camurus Braeburn Inc. Scilex Holding Mesoblast Limited AnGes MG, Inc. Kolon Life Science Eliem Therapeutics Allodynic Therapeutics Frontier Biotechnologies DiscGenics Inc. SpineThera Stayble Therapeutics Eli Lilly and Company Persica Pharmaceuticals BioRestorative Therapies Montpellier University Hospital Related Topics Chronic Lower Back Pain Chronic Lower Back Pain Market Chronic Lower Back Pain Market Infographic